Refining Lung Cancer Care: The Emerging Role of Liquid Biopsy in Screening, Diagnosis, and Precision Oncology.
5 affiliations
- 1Euromed Research Center, Euromed University of Fes (UEMF), Fes 30000, Morocco.
- 2Laboratory of Molecular Chemistry, Materials and Environment (LCME), Department of Geology, Environment and Health (GES), Faculty of Applied Sciences (FSA), Mohamed 1st University, Nador 62700, Morocco.
- 3Thoracic Surgery Department, Mohamed VI University Hospital Center, Tangier 90000, Morocco.
- 4Al Azhar Oncology Center, Rabat 10000, Morocco.
- 5Faculty of Medicine, Pharmacy and Dentistry, Sidi Mohamed Ben Abdellah University, Fes 30070, Morocco.
Abstract
Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide, representing a major public health challenge. Although low-dose computed tomography is currently the standard screening method for high-risk individuals to reduce mortality, its clinical performance is limited by false-positive findings and restricted accessibility. Emerging biomarker-based liquid biopsy offers a promising non-invasive approach for cancer detection. This narrative review provides a critical overview and evaluation of clinically endorsed liquid biopsy applications for guiding treatment in advanced-stage lung cancer, as well as investigational advances in liquid biopsy for early cancer detection. We also address challenges of current liquid biopsy technologies, the integration of artificial intelligence, implementation improvements, and future perspectives for their adoption into routine clinical practice. To complement this narrative review, a structured search of the ClinicalTrials.gov registry was performed to identify clinical trials evaluating liquid biopsy in lung cancer. Current evidence supports the clinical use of liquid biopsy for molecular profiling and treatment selection in advanced non-small cell lung cancer (NSCLC), whereas its application in early detection, screening, and minimal residual disease (MRD)-guided management remains investigational and requires further prospective validation. Overall, liquid biopsy represents a promising complementary approach to advance precision oncology and improve lung cancer management.
Related
- Emerging information technologies across the autism service and prevention continuum: a narrative review of screening, diagnosis, intervention, and health equity
- From missed diagnosis to lifelong survivorship: a precision oncology roadmap for equity in pediatric and AYA cancer care
- A multimodal precision oncology platform integrating genomics,single-cell transcriptomics, and functional drug screening expandstherapeutic options in pediatric brain tumors
- Multimodal AI in Hepatocellular Carcinoma: Bridging Diagnosis, Therapy and Prognosis Toward Precision Oncology.
- Refining E-detectioN Tools for Emerging mental disoRders (ENTER) to identify young people at clinical high risk for psychosis in the community: model development and internal validation
BibTeX
@article{mansour2026refining,
title = {{Refining Lung Cancer Care: The Emerging Role of Liquid Biopsy in Screening, Diagnosis, and Precision Oncology.}},
author = {Hicham Mansour and Omayma Mazouji and Ayman El Hammouti and Ihasane Alloubi and Roberto Incitti and Saïd El Kazzouli and Abdelhak Ouhajjou and Chakib Nejjari},
journal = {Cancers},
year = {2026},
month = sep,
doi = {10.3390/cancers18193140},
url = {https://europepmc.org/article/MED/42882836},
note = {CC BY},
}
RIS
TY - JOUR
TI - Refining Lung Cancer Care: The Emerging Role of Liquid Biopsy in Screening, Diagnosis, and Precision Oncology.
AU - Hicham Mansour
AU - Omayma Mazouji
AU - Ayman El Hammouti
AU - Ihasane Alloubi
AU - Roberto Incitti
AU - Saïd El Kazzouli
AU - Abdelhak Ouhajjou
AU - Chakib Nejjari
PY - 2026
DA - 2026/09/28
JO - Cancers
DO - 10.3390/cancers18193140
UR - https://europepmc.org/article/MED/42882836
AB - Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide, representing a major public health challenge. Although low-dose computed tomography is currently the standard screening method for high-risk individuals to reduce mortality, its clinical performance is limited by false-positive findings and restricted accessibility. Emerging biomarker-based liquid biopsy offers a promising non-invasive approach for cancer detection. This narrative review provides a critical overview and evaluation of clinically endorsed liquid biopsy applications for guiding treatment in advanced-stage lung cancer, as well as investigational advances in liquid biopsy for early cancer detection. We also address challenges of current liquid biopsy technologies, the integration of artificial intelligence, implementation improvements, and future perspectives for their adoption into routine clinical practice. To complement this narrative review, a structured search of the ClinicalTrials.gov registry was performed to identify clinical trials evaluating liquid biopsy in lung cancer. Current evidence supports the clinical use of liquid biopsy for molecular profiling and treatment selection in advanced non-small cell lung cancer (NSCLC), whereas its application in early detection, screening, and minimal residual disease (MRD)-guided management remains investigational and requires further prospective validation. Overall, liquid biopsy represents a promising complementary approach to advance precision oncology and improve lung cancer management.
SN - 2072-6694
ER -